GTH earnings

BEIJING, June 02, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today reported its unaudited financial results for the first quarter ended March 31, 2022. First Quarter and Recent Highlights Recorded total revenue of RMB 110.3 million (US $17.4 million) in the first quarter of 2022, representing 19.8% increase over the same period in 2021. LDT revenue was RMB 81.5 million (US $12.9 million), representing 13.5% increase over the same period in 2021.IVD re

BEIJING, May 23, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will report unaudited financial results for the first quarter ended March 31, 2022 on June 2, 2022 before the US market open. Management will host a conference call for investors at 8:30 a.m. ET (8:30 p.m. Beijing time) on Thursday, June 2, 2022. The conference call can be accessed by dialing the following numbers: United States:+1-833-239-5565China Domestic:400-820-528

BEIJING, March 29, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced its unaudited preliminary financial results for the fourth quarter and full year ended December 31, 2021. 2021 and Recent Business Highlights Therapy Selection: As of December 31, 2021, the Company had 58 hospital partners, of which 30 were IVD hospital partners. Genetron Health is continuing to enhance its in-hospital sales effort.

BEIJING, March 09, 2022 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will report unaudited financial results for the fourth quarter and full year ended December 31, 2021 on March 29, 2022 before the US market open. Management will host a conference call for investors at 8:30 a.m. ET (8:30 p.m. Beijing time) on Tuesday, March 29, 2022. The conference call can be accessed by dialing the following numbers: United States:+1-833-239-5565Chi

BEIJING, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today reported its unaudited preliminary financial results for the third quarter ended September 30, 2021. Third Quarter and Recent Highlights Financials: Recorded total revenue of RMB 152.5 million (US $23.7 million) for the third quarter of 2021, representing a 36.2% increase over the same period of 2020 LDT revenue was RMB 93.0 million (US $14.4 million) in the third quarter of 2021, repr

BEIJING, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will report unaudited financial results for the third quarter ended September 30, 2021 on November 30, 2021 before the US market open. Management will host a conference call for investors at 8:30 a.m. ET (9:30 p.m. Beijing time) on Tuesday, November 30, 2021. The conference call can be accessed by dialing the following numbers: United States:+1-332-208-9468China Domest

BEIJING, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced its unaudited preliminary financial results for the second quarter ended June 30, 2021. Second Quarter and Recent Highlights Recorded total revenue of RMB 140.5 million (US$21.8 million) for the second quarter 2021, representing a 38.1% increase over the same period of 2020.Generated LDT segment revenue with year on year growth of 15.0% to

BEIJING, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (("Genetron Health" or the "Company", NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it will report unaudited financial results for the second quarter ended June 30, 2021 on Aug 24, 2021 before the US market open. Management will host a conference call for investors at 8:30 a.m. ET (8:30 p.m. Beijing time) on Tuesday, Aug 24, 2021. The conference call can be accessed by dialing the following numbers: United States:+1-845-675-0437China Domestic:400-620-